Loading…
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-132M | $-120M | $-95M | -46.3% | - | 38.7% |
| 2024 | $0M | $-104M | $-86M | $-70M | -25.2% | - | 25.1% |
| 2023 | $0M | $-80M | $-69M | $-51M | -33.8% | - | 25.0% |
| 2022 | $0M | $-59M | $-55M | $-51M | -21.5% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 58.93 | 79.94 | 104.18 | 132.76 |
| Research And Development | - | 43.01 | 62.52 | 80.08 | 102.93 |
| Selling General And Administration | - | 15.92 | 17.43 | 24.10 | 29.83 |
| Total Expenses | - | 58.93 | 79.94 | 104.18 | 132.76 |
| Operating Income | - | -58.93 | -79.94 | -104.18 | -132.76 |
| Total Operating Income As Reported | - | -58.93 | -79.94 | -104.18 | -132.76 |
| EBITDA | - | -58.63 | -79.59 | -103.66 | -132.22 |
| Normalized EBITDA | - | -58.63 | -79.59 | -103.66 | -132.22 |
| EBIT | - | -58.93 | -79.94 | -104.18 | -132.76 |
| Interest Income | - | 3.65 | 10.81 | 17.70 | 12.82 |
| Net Interest Income | - | 3.65 | 10.81 | 17.70 | 12.82 |
| Other Non Operating Income Expenses | -0.02 | -0.05 | -0.04 | - | - |
| Other Income Expense | -0.02 | -0.05 | -0.04 | - | - |
| Interest Income Non Operating | - | 3.65 | 10.81 | 17.70 | 12.82 |
| Net Non Operating Interest Income Expense | - | 3.65 | 10.81 | 17.70 | 12.82 |
| Pretax Income | - | -55.32 | -69.13 | -86.48 | -119.95 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -55.32 | -69.13 | -86.48 | -119.95 |
| Net Income From Continuing And Discontinued Operation | - | -55.32 | -69.13 | -86.48 | -119.95 |
| Net Income From Continuing Operation Net Minority Interest | - | -55.32 | -69.13 | -86.48 | -119.95 |
| Net Income | - | -55.32 | -69.13 | -86.48 | -119.95 |
| Net Income Common Stockholders | - | -55.32 | -69.13 | -86.48 | -119.95 |
| Net Income Including Noncontrolling Interests | - | -55.32 | -69.13 | -86.48 | -119.95 |
| Normalized Income | - | -55.32 | -69.13 | -86.48 | -119.95 |
| Diluted NI Availto Com Stockholders | - | -55.32 | -69.13 | -86.48 | -119.95 |
| Basic Average Shares | 13.78 | 41.88 | 42.70 | 57.22 | - |
| Diluted Average Shares | 13.78 | 41.88 | 42.70 | 57.22 | - |
| Reconciled Depreciation | - | 0.30 | 0.36 | 0.52 | 0.55 |
| General And Administrative Expense | - | 15.92 | 17.43 | 24.10 | 29.83 |
| Other Gand A | - | 15.92 | 17.43 | 24.10 | 29.83 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Tyra Biosciences, Inc.this co. | TYRA | $1.6B | -13.48 | 6.24 | -46.3% | -11.68 |
| Palvella Therapeutics, Inc. | PVLA | $1.6B | -39.48 | 58.85 | -149.1% | -44.28 |
| Innoviva, Inc. | INVA | $1.6B | 6.03 | 1.39 | 23.1% | 3.66 |
| Fortrea Holdings Inc. | FTRE | $1.6B | - | 2.90 | -175.0% | - |
| Capricor Therapeutics, Inc. | CAPR | $1.6B |
| - |
| - |
| - |
| - |
| -15.41 |
| 5.29 |
| -34.4% |
| -13.44 |
| Syndax Pharmaceuticals, Inc. | SNDX | $1.6B | -5.59 | 24.71 | -441.6% | -7.18 |
| Amylyx Pharmaceuticals, Inc. | AMLX | $1.6B | -10.99 | 5.21 | -47.4% | -8.97 |
| agilon health, inc. | AGL | $1.6B | - | 12.54 | -308.8% | - |
| Nurix Therapeutics, Inc. | NRIX | $1.6B | - | 2.93 | -49.1% | - |
| Peer Median | - | -10.99 | 5.25 | -99.1% | -8.97 | |